Novartis announced Phase II primary endpoint data showing the investigational, first-in-class, oral, targeted factor B inhibitor iptacopan reduced protein in the urine – an increasingly recognized surrogate marker correlating with progression to kidney failure – and showed promise in stabilizing kidney function in patients with IgA nephropathy (IgAN).
Sanofi is halting a pivotal Phase II/III kidney disease trial for venglustat, a novel molecule designed to slow disease progression by inhibiting abnormal accumulation of glycosphingolipids.
The U.S. Food and Drug Administration approved Aurinia Pharmaceuticals Inc.’s Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis.
Shares of Calliditas Therapeutics soared in trading after the company announced positive Phase III data from a study of Nefecon in IgA nephropatjhy (IgAN), an autoimmune renal disease.
FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease Published: Oct. 26, 2020 By Mark Terry BioSpace FibroGen presented data from two pooled analyses from its roxadustat global Phase III development program this weekend at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined conference. The analyses looked at associations between the […]
Novartis released promising interim Phase II data of iptacopan in C3 glomerulopathy (C3G) at the virtual American Society of Nephrology 2020 Annual Meeting.
Alexion Pharmaceuticals shuttered the company’s oral small molecule Factor D inhibitor program for a rare kidney disease following disappointing clinical data.
AstraZeneca reported successful results from the company’s Phase III DAPA-CKD clinical trial of Farxiga (dapagliflozin) in end-stage kidney disease.
The U.S. Food and Drug Administration accepted the filing of Aurinia Pharmaceuticals Inc.’s New Drug Application (NDA) for voclosporin as a potential treatment for lupus nephritis, a serious inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus.
A new campaign from Horizon Therapeutics called Down and Out Kidney sheds light on the prevalence and impact of gout in chronic kidney disease, and aims to facilitate an important conversation with nephrologists – kidney specialists – particularly during National Kidney Month (March).